Another first copy of Dongyang Sunshine "Entacapone Film" is about to be approved

On March 15th, the NMPA official website showed that Guangdong Dongyang Sunshine Pharmaceutical Co.

Entacapone (trade name: Comtan) is a specific peripheral catecholamine-o-methyltransferase (COMT) inhibitor developed by Orion in Finland, which works by inhibiting COMT enzyme to reduce the metabolism of levodopa.

Parkinson’s disease (PD) is a common chronic degenerative disease of the nervous system in the elderly.

According to GlobalHealth Data's 2017 data, there are about 2.

COMT inhibitors are clearly recommended by European, American and domestic treatment guidelines, and are first-line drugs that assist dopamine in the treatment of Parkinson's disease patients.

The original research Entacapone was approved in China in May 2004 under the trade name Kedan.

According to the Insight database, currently 4 domestic companies have begun to deploy the entacapone generic drug market.

From the Insight database (http://db.